ASCO GUIDELINES Bundle

Osteoporosis in Survivors of Adult Cancers with Non-Metastatic Disease

ASCO GUIDELINES App Bundle brought to you fcourtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/1475491

Contents of this Issue

Navigation

Page 8 of 9

Table 4. Estimated Drug Costs for Bone Modifying Agents a Agent, Route Dose Schedule Price (USD) Total Approximate Cost Per 1-Year Treatment Cycle (USD) Oral Bisphosphonates Alendronate 5 mg 35 mg 70 mg Daily Once a week Once a week $6.50/month $6.50/month $6.50/month $78 (6.50 × 12) $78 (6.50 × 12) $78 (6.50 × 12) Risedronate 5 mg 35 mg 150 mg Daily Weekly (35 mg ) or monthly (150 mg ) $6.50/month $35.46/month $69.81/month $78 (6.50 × 12) $425.52 (35.46 × 12) $837.72 (69.81 × 12) Ibandronate 150 mg Once a month $25.86/month $310.32 (25.86 × 12) Intravenous (IV) Bisphosphonates Zoledronic acid 4 mg 5 mg 5 mg Every 6 months Yearly Every other year $46.40 ($11.599 × 4) $58.00 ($11.599 × 5) $58.00 ($11.599 × 5) $92.79 (46.40 × 2) b $58.00 b $29.00 b Monoclonal antibodies Denosumab, (subcutaneous injection) 60 mg Every 6 months $1146.24 ($19.104 × 60) $2292.48 ($1146.24 × 2) a Prices Per Dose were for a single infusion or per single injection. Prices for drugs reimbursed through Medicare Part B only were identified from the July 2019 Medicare Payment Allowable Part B Drugs Average Sales Price (ASP) Data (https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Part- B-Drugs/McrPartBDrugAvgSalesPrice/2019ASPFiles.html). Prices for orally administered drugs reimbursed through Medicare Part D were identified in the PlanFinder for a beneficiary living within ZIP code 10065. Drug costs may vary by plan and by pharmacy where a medication is filled (e.g., preferred or non-preferred pharmacies). b Does not include costs of administration or facility charges.

Articles in this issue

Links on this page

Archives of this issue

view archives of ASCO GUIDELINES Bundle - Osteoporosis in Survivors of Adult Cancers with Non-Metastatic Disease